Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
GlobalFoundries Chief Legal Officer Azar Samak L sold 500 ordinary shares on April 2, 2026, at $42.96 per share for a total of $21,480. The sale was executed under a Rule 10b5-1 trading plan adopted before the majority shareholder offering and was permitted under an existing lock-up agreement that expires May 10, 2026. The company is also pursuing …
A director of Huron Consulting Group Inc. executed an automated sale of 126 shares on April 2, 2026, under a pre-arranged Rule 10b5-1 plan, while the company reported fourth-quarter results that topped analyst estimates. Despite the quarter's outperformance, a broad 2026 guidance range and questions about artificial intelligence's potential impact …
Debra Zumwalt, a director at Huron Consulting Group Inc (HURN), sold 170 shares on April 2, 2026, under a Rule 10b5-1 plan. The transaction totaled $21,578. The company recently reported better-than-expected fourth-quarter results, but management left a wide guidance range for 2026 amid questions about how artificial intelligence may affect the bus…
Chewy Inc. general counsel and corporate secretary Hu Da-Wai sold 8,149 shares of Class A common stock on April 1, 2026, at $26.91 per share, a transaction worth $219,289. The filing shows a mosaic of restricted stock units and performance-based awards remaining in Hu’s holdings. Meanwhile, analysts have adjusted price targets and recommendations f…
Japan Post Holdings Co., Ltd. sold 20,100 shares of Aflac Inc. (NYSE: AFL) on April 2, 2026, in two transactions that together totaled roughly $2.2 million, according to a Form 4 filing. The insurer's shares trade near $110 and carry a market value of about $56.68 billion. Recent company results showed a revenue beat but an earnings shortfall, and …
Jorey Chernett, a 10% owner of AirSculpt Technologies, purchased 90,000 shares on April 3, 2026, at a weighted average price of $2.82 for a total outlay of $253,800, according to a Form 4 filing. The buy occurred as the stock has risen sharply year-to-date and after the company reported fourth-quarter 2025 results that modestly exceeded consensus e…
Chief Commercial Officer Bruno Thomas purchased 10,000 shares of Culp Inc common stock on April 2, 2026, spending $27,650 on shares priced between $2.75 and $2.78. The transaction leaves Thomas with 90,000 shares directly held. The trade comes as the stock changes hands at $2.71, roughly 1% above its 52-week low of $2.70, and after the company repo…
Spyre Therapeutics' CFO Scott L. Burrows sold 7,500 shares on April 1, 2026, realizing roughly $370,076, and exercised options to acquire 7,500 shares at $14.50 the same day. The stock trades near its 52-week high amid accelerated clinical timelines and several analyst target increases, while an InvestingPro analysis flags the shares as overvalued …
Fold Holdings Chief Executive William Brian Poppic Reeves sold 5,710 shares of the company's common stock on April 2, 2026, in a transaction disclosed on a Form 4 filing. The sale, executed at $1.222 per share for a total of $6,977, was made to satisfy tax withholding related to the vesting and settlement of restricted stock units and was not discr…
Spyre Therapeutics Chief Executive Officer Turtle Cameron sold 15,000 shares of common stock on April 1, 2026, for roughly $739,912, according to a Form 4 filing. The transactions took place under a Rule 10b5-1 trading plan adopted June 20, 2025. The sales occurred as Spyre's share price sits near its 52-week high amid accelerated clinical timeline…
Spyre Therapeutics NASDAQ:SYRE Chief Medical Officer Sloan Sheldon sold 7,958 shares on April 1, 2026, at $50.00 per share, generating $397,900, and on the same day exercised options to buy 7,958 shares at $21.66 per share for $172,370. Following the transactions, Sheldon holds no direct shares. The trades were carried out under a Rule 10b5-1 plan …
Fold Holdings Chief Technology Officer Thomas J. Dickman sold six shares of common stock on April 2, 2026, for a total of $7 to satisfy tax withholding obligations after acquiring 17 shares on April 1. The insider activity comes as Fold shares trade near their 52-week low and the company reports a revenue miss for fiscal 2025 Q4 alongside declining…
Fold Holdings CFO Wolfe Repass sold 1,326 shares on April 2, 2026, to satisfy tax-withholding obligations tied to the vesting and settlement of restricted stock units. The transaction, described as non-discretionary, coincides with a period in which Fold's shares have declined sharply and the company reported a revenue miss for fiscal 2025 Q4, prom…
Brian M. Venturo, Chief Strategy Officer of CoreWeave, Inc. (NASDAQ: CRWV), sold $111.6 million worth of Class A common stock across transactions on April 1 and April 2, 2026, carried out under a pre-established 10b5-1 trading arrangement. The disposals took place at per-share prices between $77.4269 and $81.2986, and coincided with conversions of …
Daniel Rabinowitz, SEC and Chief Legal Officer of Natera, Inc. (NASDAQ: NTRA), sold 8,400 shares of common stock on April 1, 2026 under a Rule 10b5-1 trading plan. The trades amounted to $1.7 million at weighted average prices between $200.7868 and $205.0026 per share. The disclosures come as Natera shares trade at $207.98, up 55% over the past yea…
Solomon Moshkevich, Natera's President of Clinical Diagnostics, sold 3,000 shares on April 1, 2026, in three tranches under a Rule 10b5-1 plan, generating roughly $606,899. The sales occurred at prices between $201.32 and $203.31 per share. Natera has announced product and corporate developments while trading above InvestingPro’s Fair Value and sho…
CoreWeave CEO and President Michael N. Intrator, a director and 10% owner, sold 418,722 shares of Class A Common Stock on April 1, 2026, for approximately $34.9 million under a Rule 10b5-1 plan. The company also disclosed benchmark performance gains on Nvidia GB200 and GB300 systems and the closing of an $8.5 billion delayed draw term loan facility…
Sean Searby, executive vice president and chief information and operations officer at Amalgamated Financial Corporation (NASDAQ: AMAL), sold 4,948 shares on April 1, 2026, for roughly $195,048 under an existing Rule 10b5-1 trading plan. Separately, 330 shares were withheld related to a vested restricted stock unit installment. The company reported …
Rambus INC President and CEO Seraphin Luc sold 5,426 shares of common stock on April 2, 2026, for approximately $470,188 under a prearranged Rule 10b5-1 plan. The company reported fourth-quarter 2025 EPS of $0.68 and revenue of $190.2 million, announced the HBM4E Memory Controller IP for next-generation AI and graphics workloads, and initiated a se…
Apogee Therapeutics Chief Medical Officer Carl Dambkowski sold 5,500 shares on April 1, 2026, for roughly $466,619 and concurrently exercised options to acquire 4,125 shares. The transactions take place amid strong share-price performance, recent public offerings that raised hundreds of millions of dollars, and analyst activity that includes upward…
Apogee Therapeutics Chief Financial Officer Henderson Jane sold 2,000 shares on April 1, 2026, in two tranches for roughly $170,020. The transaction occurred while the stock traded close to its 52-week high and after the company completed a sizable public offering and published clinical data that prompted analyst optimism.
Immunome Inc. (NASDAQ:IMNM) Chief Financial Officer Rosett Max sold 65,000 shares on April 2, 2026, for roughly $1.4 million and exercised options to acquire 71,561 shares. The trades were completed under a Rule 10b5-1 plan adopted in December 2025, leaving Rosett Max with 54,037 direct shares. Market coverage and analyst commentary signal continue…
Immunome Inc. Chief Scientific Officer Jack Higgins sold 9,438 shares on April 2, 2026, through a pre-arranged Rule 10b5-1 plan for $21.64 per share, totaling $204,238. Post-transaction, Higgins retains 22,000 directly held shares and has custodial holdings subject to a lock-up. The company trades near $21.84 with a market capitalization of $2.47 b…
Ciena Corp. reported that Jason Phipps, the company’s Senior Vice President of Global Sales and Marketing, sold 18,535 shares of common stock on April 1, 2026, for about $9.02 million. The transactions were filed on a Form 4 and were executed under a Rule 10b5-1 trading plan. The insider sale occurs while the stock trades close to its 52-week high …
Deanna H. Lund, Executive Vice President and Chief Financial Officer of Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), sold 5,000 shares of the company's common stock on April 1, 2026, under a previously adopted 10b5-1 trading plan. The transactions, carried out at prices ranging from $68.0578 to $72.45, amounted to $348,129. Kratos mean…
